Adaptive Biotechnologies reports Q1 2026 revenue up 35%, boosts full-year MRD revenue guidance.

Adaptive Biotechnologies reported strong Q1 2026 results with revenue of $70.9 million, a 35% increase from the previous year, driven mainly by a 53% growth in its Minimal Residual Disease (MRD) business. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting growing adoption of its MRD platform in clinical testing and drug development. Despite a net loss of $20 million, the loss narrowed compared to last year, and adjusted EBITDA loss also improved. Adaptive Biotechnologies plans to sustain growth with multiple drivers and will provide further outlook details in an upcoming conference call.